Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 02 Apr 2022]

 

Why COVID vaccines for young children (5–11 years) are not essential at this moment in time?
The Joint Committee on Vaccination and Immunisation (JCVI) in UK has recently advised that COVID vaccines in 5–11-year-old children is non-essential. This has created an outrage among some healthcare professio…
Authors: Hamid A. Merchant
Citation: Journal of Pharmaceutical Policy and Practice 2022 15:25
Content type: Commentary Published on: 28 March 2022

Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study

The Lancet
Apr 02, 2022 Volume 399 Number 10332 p1279-1358, e20-e29
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
Tommy Nyberg, et al. COVID-19 Genomics UK (COG-UK) consortium,
Open Access

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India

The Lancet
Apr 02, 2022 Volume 399 Number 10332 p1279-1358, e20-e29
https://www.thelancet.com/journals/lancet/issue/current

 

Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
Akash Khobragade, et al. on behalf of the ZyCoV-D phase 3 Study Investigator Group

A roadmap of recovery for the COVID generation

The Lancet Child & Adolescent Health
Apr 2022 Volume 6 Number 4 p215-278, e13-e15
https://www.thelancet.com/journals/lanchi/issue/current

 

Editorial
A roadmap of recovery for the COVID generation
The Lancet Child & Adolescent Health
… The pandemic has had wide-ranging and long-lasting effects on young people, but children’s developmental plasticity and resilience give us room for optimism. As the world moves into the next phase of pandemic recovery and living with COVID-19, we must grasp this opportunity to support every child to catch up and thrive. The Lancet Child & Adolescent Health will be publishing a Commission to build a roadmap of recovery for this COVID generation. We call for collaborators and research from all aspects of child and adolescent health—particularly from our colleagues in development, social science, and adolescent health—to join us.

Global, regional, and national minimum estimates of children affected by COVID-19-associated orphanhood and caregiver death, by age and family circumstance up to Oct 31, 2021: an updated modelling study

The Lancet Child & Adolescent Health
Apr 2022 Volume 6 Number 4 p215-278, e13-e15
https://www.thelancet.com/journals/lanchi/issue/current

 

Articles
Global, regional, and national minimum estimates of children affected by COVID-19-associated orphanhood and caregiver death, by age and family circumstance up to Oct 31, 2021: an updated modelling study
H Juliette T Unwin,et al.
Open Access

Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study

Lancet Global Health
Apr 2022 Volume 10 Number 4 e448-e584
https://www.thelancet.com/journals/langlo/issue/current

 

Articles
Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study
Yusuke Shimakawa,et al.

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses

Lancet Infectious Diseases
Apr 2022 Volume 22 Number 4p 427-562, e101-e127
https://www.thelancet.com/journals/laninf/issue/current

 

Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses
Ramachandran Thiruvengadam, et al. on behalf of the Department of Biotechnology India Consortium for COVID-19 research

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Lancet Infectious Diseases
Apr 2022 Volume 22 Number 4p 427-562, e101-e127
https://www.thelancet.com/journals/laninf/issue/current

 

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
Gang Zeng, et al.

Mass drug administration of ivermectin and dihydroartemisinin–piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia

Lancet Infectious Diseases
Apr 2022 Volume 22 Number 4p 427-562, e101-e127
https://www.thelancet.com/journals/laninf/issue/current

 

Mass drug administration of ivermectin and dihydroartemisinin–piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia
Edgard D Dabira, et al.

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial

Lancet Infectious Diseases
Apr 2022 Volume 22 Number 4p 427-562, e101-e127
https://www.thelancet.com/journals/laninf/issue/current

 

Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial
Ganesh Kumar Rai, et al.

Effectiveness of nationwide programmatic testing and treatment for latent tuberculosis infection in migrants in England: a retrospective, population-based cohort study

Lancet Public Health
Apr 2022 Volume 7 Number 4 e291-e390
https://www.thelancet.com/journals/lanpub/issue/current

 

Articles
Effectiveness of nationwide programmatic testing and treatment for latent tuberculosis infection in migrants in England: a retrospective, population-based cohort study
Luis C Berrocal-Almanza, et al

COVID-19 vaccine coverage and factors associated with vaccine uptake among 23 247 adults with a recent history of homelessness in Ontario, Canada: a population-based cohort study

Lancet Public Health
Apr 2022 Volume 7 Number 4 e291-e390
https://www.thelancet.com/journals/lanpub/issue/current

 

COVID-19 vaccine coverage and factors associated with vaccine uptake among 23 247 adults with a recent history of homelessness in Ontario, Canada: a population-based cohort study
Salimah Z Shariff, et al.

SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys

Lancet Respiratory Medicine
Apr 2022 Volume 10 Number 4 p313-420, e34-e43
https://www.thelancet.com/journals/lanres/issue/current

 

Articles
SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): a series of cross-sectional random community surveys
Marc Chadeau-Hyam, et al. in collaboration with the COVID-19 Genomics UK consortium
Open Access

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study

Lancet Respiratory Medicine
Apr 2022 Volume 10 Number 4 p313-420, e34-e43
https://www.thelancet.com/journals/lanres/issue/current

 

Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study
Ruvim Izikson, et al.

COVID-19 prevention behaviors, trust, and intent to vaccinate among youth at risk for HIV

PLoS One
http://www.plosone.org/
[Accessed 02 Apr 2022]

 

Research Article
COVID-19 prevention behaviors, trust, and intent to vaccinate among youth at risk for HIV
Joan Christodoulou, Anne E. Fehrenbacher, Elizabeth H. Shaw, Eleanor M. Vincent, Jessica L. Saleska
Research Article | published 31 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266321

COVID-19 vaccine hesitancy among marginalized populations in the U.S. and Canada: Protocol for a scoping review

PLoS One
http://www.plosone.org/
[Accessed 02 Apr 2022]

 

COVID-19 vaccine hesitancy among marginalized populations in the U.S. and Canada: Protocol for a scoping review
Peter A. Newman, Luke Reid, Suchon Tepjan, Sophia Fantus, Kate Allan, Thabani Nyoni, Adrian Guta, Charmaine C. Williams
Study Protocol | published 31 Mar 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0266120

Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: A systematic review and meta-analysis

Preventive Medicine
Volume 157 April 2022
https://www.sciencedirect.com/journal/preventive-medicine/vol/157/suppl/C

 

Review article Full text access
Willingness, refusal and influential factors of parents to vaccinate their children against the COVID-19: A systematic review and meta-analysis
Petros Galanis, Irene Vraka, Olga Siskou, Olympia Konstantakopoulou, … Daphne Kaitelidou
Article 106994

Filling the gaps

Science
Volume 376| Issue 6588| 1 Apr 2022
https://www.science.org/toc/science/current

 

Special issue – Completing the human genome
Introduction to Special Issue
Filling the gaps
BY Laura M. Zahn
31 Mar 2022: 42-43
A fully sequenced human genome was triumphantly announced more than 20 years ago. However, owing to technological limitations, some genomic regions remained unresolved. Here, Science presents research by the Telomere-to-Telomere (T2T) Consortium, reporting on the endeavor to complete a comprehensive human reference genome. Generated primarily by long-read sequencing of a hydatidiform mole, a doubly haploid growth, this effort adds ∼200 megabases of genetic information—a full chromosome’s worth—to the human genome.

Through the resolution of previously unsequenceable and unalignable regions, mostly composed of highly repetitive sequences, this reference genome allows for a detailed characterization of the centromeric satellite repeats, transposable elements, and segmental duplications. Mapping of genomic sequences, including those from previously published studies, resolves aspects of human genetic diversity, including evolutionary comparisons with our primate relatives. Furthermore, it allows for identification of how changes in methylation density differ within and among centromeres and how epigenetics can affect the transcription of repeat sequences.

These investigations have only begun to tease apart how the T2T reference genome influences the detection of biomedically relevant variants and the evolution of genomic regions that determine human traits. Although much remains to be discovered, the T2T reference genome provides another celebratory benchmark to observe as we continue to delve into the genetics that underlie our complete selves.

The complete sequence of a human genome

Science
Volume 376| Issue 6588| 1 Apr 2022
https://www.science.org/toc/science/current

 

The complete sequence of a human genome
BY Sergey Nurk et al [89 authors]
31 Mar 2022: 44-53
Abstract
Since its initial release in 2000, the human reference genome has covered only the euchromatic fraction of the genome, leaving important heterochromatic regions unfinished. Addressing the remaining 8% of the genome, the Telomere-to-Telomere (T2T) Consortium presents a complete 3.055 billion–base pair sequence of a human genome, T2T-CHM13, that includes gapless assemblies for all chromosomes except Y, corrects errors in the prior references, and introduces nearly 200 million base pairs of sequence containing 1956 gene predictions, 99 of which are predicted to be protein coding. The completed regions include all centromeric satellite arrays, recent segmental duplications, and the short arms of all five acrocentric chromosomes, unlocking these complex regions of the genome to variational and functional studies.

The trillion dollar vaccine gap

Science Translational Medicine
Volume 14| Issue 638| 30 Mar 2022
https://www.science.org/toc/stm/current

 

Viewpoint
The trillion dollar vaccine gap
BY Simone Pecetta…Rino Rappuoli
30 Mar 2022
Global public investment and a renewed focus on vaccine economics are necessary to prevent new pandemics and grant equitable vaccine access worldwide.
Abstract
New technologies and unprecedented public investment have transformed vaccine development and allowed fast delivery of safe and efficacious COVID-19 vaccines, mitigating the impact of the pandemic on health and the economy. A quantum change in public …

Optimmunize: Improving the Beneficial Effects of Vaccines

Vaccine
Volume 40, Issue 11, Pages 1513-1680 (8 March 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/11

 

Optimmunize: Improving the Beneficial Effects of Vaccines
Editorial Full text access
Introduction
Eleanor N. Fish, Christine S. Benn, Sabra L. Klein
There is increasing evidence that vaccines, in addition to their disease-specific effects, have important off-target or non-specific effects (NSEs). A number of major observations with significant implications for child survival have been identified (Table 1).

Epidemiological studies have consistently found differential effects of live and non-live vaccines on overall mortality. Live vaccines have beneficial NSEs. Non-live vaccines may increase mortality, particularly for females, in spite of their pathogen-specific disease-protective effects. Many studies have focused on Bacillus Calmette-Guérin (BCG), where BCG has been shown to have beneficial NSEs in both animal and human challenge studies. Notably, different strains of BCG have different NSEs.

A growing number of studies have shown that vaccines may induce epigenetic changes, which can reprogram the innate immune system. Some vaccines will induce innate immune training, leading to an increased immune response to subsequent unrelated pathogens. Others may lead to innate immune tolerance, thereby rendering the recipient less likely to respond appropriately to subsequent unrelated challenges.

In February 2020, the 1st Optimmunize Conference was held at the Wellcome Genome Campus in Hinxton, near Cambridge, UK. The aim of the conference was to bring together epidemiologists, clinicians and immunologists to discuss and explore the underlying immunologic and genetic bases of NSEs, how generalizable they are, whether they can prove useful in geriatric and veterinary medicine, and why the NSEs often differ between sexes. This Special Issue provides a selection of the papers arising from the Conference….

Pre-Print Servers

Pre-Print Servers

 

Gates Open Research
https://gatesopenresearch.org/browse/articles

Research Article metrics
Revised
Integration of HIV prevention and sexual and reproductive health in the era of anti-retroviral-based prevention: findings from assessments in Kenya, Malawi and Zimbabwe [version 2; peer review: 3 approved with reservations]
Fannie Kachale, Imelda Mahaka, Fatima Mhuriro, Mary Mugambi, Joseph Murungu, Barbra Ncube, Getrude Ncube, Albert Ndwiga, Rose Nyirenda, Violet Otindo, Anna Carter, Megan Dunbar, Janet Fleischman, Jessica Rodrigues, Kate Segal
Peer Reviewers Morkor Newman Owiredu; Daniel K. Were; Rose Patricia Oluoch
Funder
Bill and Melinda Gates Foundation
LATEST VERSION PUBLISHED 28 Mar 2022

 

medRxiv
https://www.medrxiv.org/content/about-medrxiv
medRxiv is a free online archive and distribution server for complete but unpublished manuscripts (preprints) in the medical, clinical, and related health sciences. Preprints are preliminary reports of work that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information. medRxiv is for the distribution of preprints – complete but unpublished manuscripts – that describe human health research conducted, analyzed, and interpreted according to scientific principles…

COVID-19 vaccination coverage by company size and the effects of socioeconomic factors and workplace vaccination in Japan: a cohort study
Koji Mori, Takahiro Mori, Tomohisa Nagata, Hajime Ando, Ayako Hino, Seiichiro Tateishi, Mayumi Tsuji, Keiji Muramatsu
medRxiv 2022.03.30.22273203; doi: https://doi.org/10.1101/2022.03.30.22273203

Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial
Joon Young Song, Won Suk Choi, Jung Yeon Heo, Jin Soo Lee, Dong Sik Jung, Shin-Woo Kim, Kyung Hwa Park, Joong Sik Eom, Su Jin Jeong, Jacob Lee, Ki Tae Kwon, Hee Jung Choi, Jang Wook Sohn, Young Keun Kim, Ji Yun Noh, Woo Joo Kim, François Roman, Maria Angeles Ceregido, Francesca Solmi, Agathe Philippot, Alexandra C. Walls, Lauren Carter, David Veesler, Neil King, Hun Kim, Ji Hwa Ryu, Su Jeen Lee, Yong Wook Park, Ho keun Park, Hee Jin Cheong
medRxiv 2022.03.30.22273143; doi: https://doi.org/10.1101/2022.03.30.22273143

Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection.
Sabryna Nantel, Benoite Bourdin, Kelsey Adams, Julie Carbonneau, Henintsoa Rabezanaha, Marie-Eve Hamelin, Deirdre McCormack, Patrice Savard, Yves Longtin, Matthew Cheng, Gaston DeSerres, Jacques Corbeil, Vladimir Gilca, Mariana Baz, Guy Boivin, Caroline Quach, Helene Decaluwe
medRxiv 2022.03.29.22272714; doi: https://doi.org/10.1101/2022.03.29.22272714

Effect of vaccination rates on the prevalence and mortality of COVID-19
Jacob Westerhout, Hamid Khataee, Zoltan Neufeld
medRxiv 2022.03.31.22273274; doi: https://doi.org/10.1101/2022.03.31.22273274

Uptake of COVID-19 vaccines among pregnant women: a systematic review and meta-analysis
Petros A Galanis, Irene Vraka, Olga Siskou, Olympia Konstantakopoulou, Aglaia Katsiroumpa, Daphne Kaitelidou
medRxiv 2022.04.01.22273296; doi: https://doi.org/10.1101/2022.04.01.22273296

Interpretation of non-responders to SARS-CoV-2 vaccines using WHO International Standard
Qiang Zeng, Xue Yang, Qi Gao, Biao-yang Lin, Yong-zhe Li, Gang Huang, Yang Xu
medRxiv 2022.03.31.22273272; doi: https://doi.org/10.1101/2022.03.31.22273272

Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation: test negative case-control study
Julia Stowe, Nick Andrews, Freja Kirsebom, Mary Ramsay, Jamie Lopez Bernal
medRxiv 2022.04.01.22273281; doi: https://doi.org/10.1101/2022.04.01.22273281

Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial
Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, Alpha Diallo, Christelle Delmas, Juliette Saillard, Aline Dechanet, Claire Fougerou, Minh-Patrick Lê, Gilles Peytavin, Noémie Mercier, Priyanka Velou, Sarah Tubiana, Xavier Lescure, Emmanuel Faure, Saad Nseir, Jean-Christophe Richard, Florent Wallet, François Goehringer, Benjamin Lefèvre, Antoine Kimmoun, François Raffi, Benjamin Gaborit, Jean Reignier, Jean-Philippe Lanoix, Claire Andrejak, Yoann Zerbib, Firouzé Bani-Sadr, Bruno Mourvilliers, François Danion, Yvon Ruch, Raphaël Clere-Jehl, Vincent Le Moing, Kada Klouche, Karine Lacombe, Guillaume Martin-Blondel, Fanny Vardon-Bounes, André Cabié, Jean-Marie Turmel, Lionel Piroth, Mathieu Blot, Élisabeth Botelho-Nevers, Amandine Gagneux-Brunon, Guillaume Thiery, François Bénézit, Rostane Gaci, Joy Mootien, Sébastien Gallien, Denis Garot, Kevin Bouiller, Loïc Epelboin, Stéphane Jauréguiberry, Alexandre Gaymard, Gil Verschelden, Sandra Braz, Joao Miguel Ferreira Ribeiro, Michael Joannidis, Thérèse Staub, Antoine Altdorfer, Richard Greil, Alexander Egle, Jérémie Guedj, Marion Noret, Roberto Roncon-Albuquerque, Jose-Artur Paiva, Bruno Lina, Dominique Costagliola, Yazdan Yazdanpanah, Charles Burdet, France Mentré
medRxiv 2022.03.30.22273206; doi: https://doi.org/10.1101/2022.03.30.22273206

Effectiveness of Typhoid Conjugate Vaccine in Zimbabwe used in response to an outbreak among children and young adults: a matched case control study
Maria S. Lightowler, Portia Manangazira, Fabienne Nackers, Michel Van Herp, Isaac Phiri, Kuziwa Kuwenyi, Isabella Panunzi, Daniela Garone, Farayi Marume, Andrew Tarupiwa, Eva Ferreras, Clemence Duri, Francisco J. Luquero
medRxiv 2022.03.28.22273032; doi: https://doi.org/10.1101/2022.03.28.22273032

Reducing societal impacts of SARS-CoV-2 interventions through subnational implementation
Mark M. Dekker, Luc E. Coffeng, Frank P. Pijpers, Debabrata Panja, Sake J. de Vlas
medRxiv 2022.03.31.22273222; doi: https://doi.org/10.1101/2022.03.31.22273222

Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative
Guillaume Butler-Laporte, Gundula Povysil, Jack Kosmicki, Elizabeth T Cirulli, Theodore Drivas, Simone Furini, Chadi Saad, Axel Schmidt, Pawel Olszewski, Urszula Korotko, Mathieu Quinodoz, Elifnaz Çelik, Kousik Kundu, Klaudia Walter, Junghyung Jung, Amy D Stockwell, Laura G Sloofman, Alexander W Charney, Daniel Jordan, Noam Beckmann, Bartlomiej Przychodzen, Timothy Chang, Tess D Pottinger, Ning Shang, Fabian Brand, Francesca Fava, Francesca Mari, Karolina Chwialkowska, Magdalena Niemira, Szymon Pula, J Kenneth Baillie, Alex Stuckey, Andrea Ganna, Konrad J Karczewski, Kumar Veerapen, Mathieu Bourgey, Guillaume Bourque, Robert JM Eveleigh, Vincenzo Forgetta, David Morrison, David Langlais, Mark Lathrop, Vincent Mooser, Tomoko Nakanishi, Robert Frithiof, Michael Hultström, Miklos Lipcsey, Yanara Marincevic-Zuniga, Jessica Nordlund, Kelly M. Schiabor Barrett, William Lee, Alexandre Bolze, Simon White, Stephen Riffle, Francisco Tanudjaja, Efren Sandoval, Iva Neveux, Shaun Dabe, Nicolas Casadei, Susanne Motameny, Manal Alaamery, Salam Massadeh, Nora Aljawini, Mansour S. Almutairi, Yaseen M. Arabi, Saleh A. Alqahtan, Fawz S. Al Harthi, Amal Almutairi, Fatima Alqubaishi, Sarah Alotaibi, Albandari Binowayn, Ebtehal A. Alsolm, Hadeel El Bardisy, Mohammad Fawzy, COVID-19 Host Genetics Initiative, DeCOI Host Genetics Group, GEN-COVID Multicenter Study, GenOMICC Consortium, Japan COVID-19 Task Force, Regeneron Genetics Center, Daniel H Geschwind, Stephanie Arteaga, Alexis Stephens, Manish J. Butte, Paul C. Boutros, Takafumi N. Yamaguchi, Shu Tao, Stefan Eng, Timothy Sanders, Paul J. Tung, Michael E. Broudy, Yu Pan, Alfredo Gonzalez, Nikhil Chavan, Ruth Johnson, Bogdan Pasaniuc, Brian Yaspan, Sandra Smieszek, Carlo Rivolta, Stephanie Bibert, Pierre-Yves Bochud, Maciej Dabrowski, Pawel Zawadzki, Mateusz Sypniewski, Elżbieta Kaja, Pajaree Chariyavilaskul, Voraphoj Nilaratanakul, Nattiya Hirankarn, Vorasuk Shotelersuk, Monnat Pongpanich, Chureerat Phokaew, Wanna Chetruengchai, Yosuke Kawai, Takanori Hasegawa, Tatsuhiko Naito, Ho Namkoong, Ryuya Edahiro, Akinori Kimura, Seishi Ogawa, Takanori Kanai, Koichi Fukunaga, Yukinori Okada, Seiya Imoto, Satoru Miyano, Serghei Mangul, Malak S Abedalthagafi, Hugo Zeberg, Joseph J Grzymski, Nicole L Washington, Stephan Ossowski, Kerstin U Ludwig, Eva C Schulte, Olaf Riess, Marcin Moniuszko, Miroslaw Kwasniewski, Hamdi Mbarek, Said I Ismail, Anurag Verma, David B Goldstein, Krzysztof Kiryluk, Alessandra Renieri, Manuel Ferreira, J Brent Richards
medRxiv 2022.03.28.22273040; doi: https://doi.org/10.1101/2022.03.28.22273040 Revision

Emerging Therapies for COVID-19: the value of information from more clinical trials
Stijntje W. Dijk, Eline Krijkamp, Natalia Kunst, Cary P. Gross, John B. Wong, M.G. Myriam Hunink
medRxiv 2022.03.29.22273041; doi: https://doi.org/10.1101/2022.03.29.22273041

Persistent health issues, adverse events of significant concern, and effectiveness of COVID-19 vaccination- findings from a real-world cohort study of healthcare workers in north India
Upinder Kaur, Sapna Bala, Aditi Joshi, Noti Taruni Srija Reddy, Chetan, Mayank Chauhan, Nikitha Pedapanga, Shubham Kumar, Anurup Mukherjee, Vaibhav Mishra, Dolly Talda, Rohit Singh, Rohit Kumar Gupta, Ashish Kumar Yadav, Poonam Jyoti Rana, Jyoti Srivastava, Shobha Bhat K, Anup Singh, Naveen Kumar PG, Manoj Pandey, Kishor Patwardhan, Sangeeta Kansal, Sankha Shubhra Chakrabarti
medRxiv 2022.03.26.22272613; doi: https://doi.org/10.1101/2022.03.26.22272613

Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines during the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)
Zoltán Kiss, István Wittmann, Lőrinc Polivka, György Surján, Orsolya Surján, Zsófia Barcza, Gergő Attila Molnár, Dávid Nagy, Veronika Müller, Krisztina Bogos, Péter Nagy, István Kenessey, András Wéber, Mihály Pálosi, János Szlávik, Zsuzsa Schaff, Zoltán Szekanecz, Cecília Müller, Miklós Kásler, Zoltán Vokó
medRxiv 2022.03.27.22273000; doi: https://doi.org/10.1101/2022.03.27.22273000

Impact of the Russian invasion of Ukraine on the COVID-19 pandemic dynamics
Igor Nesteruk
medRxiv 2022.03.26.22272979; doi: https://doi.org/10.1101/2022.03.26.22272979

Genomic epidemiology reveals the impact of national and international restrictions measures on the SARS-CoV-2 epidemic in Brazil
Marta Giovanetti, Svetoslav Nanev Slavov, Vagner Fonseca, Eduan Wilkinson, Houriiyah Tegally, José Salvatore Leister Patané, Vincent Louis Viala, James Emmanuel San, Evandra Strazza Rodrigues, Elaine Vieira Santos, Flavia Aburjaile, Joilson Xavier, Hegger Fritsch, Talita Emile Ribeiro Adelino, Felicidade Pereira, Arabela Leal, Felipe Campos de Melo Iani, Glauco de Carvalho Pereira, Cynthia Vazquez, Gladys Mercedes Estigarribia Sanabria, Elaine Cristina de Oliveira, Luiz Demarchi, Julio Croda, Rafael dos Santos Bezerra, Loyze Paola Oliveira de Lima, Antonio Jorge Martins, Claudia Renata dos Santos Barros, Elaine Cristina Marqueze, Jardelina de Souza Todao Bernardino, Debora Botequio Moretti, Ricardo Augusto Brassaloti, Raquel de Lello Rocha Campos Cassano, Pilar Drummond Sampaio Corrêa Mariani, João Paulo Kitajima, Bibiana Santos, Rodrigo Proto-Siqueira, Vlademir Vicente Cantarelli, Stephane Tosta, Vanessa Brandão Nardy, Luciana Reboredo de Oliveira da Silva, Marcela Kelly Astete Gómez, Jaqueline Gomes Lima, Adriana Aparecida Ribeiro, Natália Rocha Guimarães, Luiz Takao Watanabe, Luana Barbosa Da Silva, Raquel da Silva Ferreira, Mara Patricia F. da Penha, María José Ortega, Andrea Gómez de la Fuente, Shirley Villalba, Juan Torales, María Liz Gamarra, Carolina Aquino, Gloria Patricia Martínez Figueredo, Wellington Santos Fava, Ana Rita C. Motta-Castro, James Venturini, Sandra Maria do Vale Leone de Oliveira, Crhistinne Cavalheiro Maymone Gonçalves, Maria do Carmo Debur Rossa, Guilherme Nardi Becker, Mayra Marinho Presibella, Nelson Quallio Marques, Irina Nastassja Riediger, Sonia Raboni, Gabriela Mattoso Coelho, Allan Henrique Depieri Cataneo, Camila Zanluca, Claudia N Duarte dos Santos, Patricia Akemi Assato, Felipe Allan da Silva da Costa, Mirele Daiana Poleti, Jessika Cristina Chagas Lesbon, Elisangela Chicaroni Mattos, Cecilia Artico Banho, Lívia Sacchetto, Marília Mazzi Moraes, Rejane Maria Tommasini Grotto, Jayme A. Souza-Neto, Maurício Lacerda Nogueira, Heidge Fukumasu, Luiz Lehmann Coutinho, Rodrigo Tocantins Calado, Raul Machado Neto, Ana Maria Bispo de Filippis, Rivaldo Venancio da Cunha, Carla Freitas, Cassio Roberto Leonel Peterka, Cássia de Fátima Rangel Fernandes, Wildo Navegantes de Araújo, Rodrigo Fabiano do Carmo Said, Maria Almiron, Carlos Frederico Campelo de Albuquerque e Melo, José Lourenço, Tulio de Oliveira, Edward C. Holmes, Ricardo Haddad, Sandra Coccuzzo Sampaio, Maria Carolina Elias, Simone Kashima, Luiz Carlos Junior de Alcantara, Dimas Tadeu Covas
medRxiv 2021.10.07.21264644; doi: https://doi.org/10.1101/2021.10.07.21264644 Revision

Inconsistent directions of change in case severity across successive SARS-CoV-2 variant waves suggests an unpredictable future
David J. Pascall, Elen Vink, Guy Mollett, Rachel Blacow, Naomi Bulteel, Robyn Campbell, Alasdair Campbell, Sarah Clifford, Chris Davis, Ana da Silva Filipe, Ludmila Fjodorova, Ruth Forrest, Emily Goldstein, Rory Gunson, John Haughney, Matthew T.G. Holden, Patrick Honour, Joseph Hughes, Edward James, Tim Lewis, Martin McHugh, Yusuke Onishi, Ben Parcell, David L. Robertson, Noha El Sakka, Sharif Shabaan, James G. Shepherd, Katherine Smollett, Kate Templeton, Elizabeth Wastnedge, Thomas Williams, Tommy Nyberg, Shaun R. Seaman, Oscar MacLean, Craig Wilkie, Surajit Ray, The COVID-19 Genomics UK (COG-UK) consortium, Emma C. Thomson
medRxiv 2022.03.24.22272915; doi: https://doi.org/10.1101/2022.03.24.22272915

Wellcome Open Research [to 02 Apr 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 02 Apr 2022]

Wellcome Open Research provides all Wellcome researchers with a place to rapidly publish any results they think are worth sharing. All articles benefit from rapid publication, transparent peer review and editorial guidance on making all source data openly available.

Research Article metrics
Revised
The construction of rare disease discourse on YouTube: highlighting a disparity between policy rhetoric and patient practices around public engagement [version 2; peer review: 1 approved with reservations]
Matthew Hanchard
Peer Reviewer Narelle Warren
Funder
Wellcome
LATEST VERSION PUBLISHED 01 Apr 2022

Method Article metrics
Revised
Methodology of Natsal-COVID Wave 1: a large, quasi-representative survey with qualitative follow-up measuring the impact of COVID-19 on sexual and reproductive health in Britain [version 2; peer review: 1 approved, 1 approved with reservations]
Emily Dema, Andrew J Copas, Soazig Clifton, Anne Conolly, Margaret Blake, Julie Riddell, Raquel Boso Perez, Clare Tanton, Chris Bonell, Pam Sonnenberg, Catherine H Mercer, Kirstin R Mitchell, Nigel Field
Peer Reviewers Jamie Frankis; Laura D Lindberg
Funders
Wellcome Trust
Economic and Social Research Council
National Institute for Health Research
Medical Research Council
University College London
Chief Scientist Office
LATEST VERSION PUBLISHED 28 Mar 2022

Think Tanks

Think Tanks
 
 
Brookings
http://www.brookings.edu/
Accessed 02 Apr 2022
Essay
The economic case for federal investment in COVID-19 vaccines and therapeutics remains strong
Susan Athey, Rena M. Conti, Matthew Fiedler, Richard G. Frank, and Jonathan Gruber
Friday, April 1, 2022
 
 
Center for Global Development [to 02 Apr 2022]
https://www.cgdev.org/
Publications, Events [Selected]
Reexamining Global Health: Global Commons, Financing Priorities, and the Role of Institutions in the Global South
Event
3/28/22
The COVID-19 pandemic has showcased the large vulnerabilities of the global health architecture and weaknesses in the resilience of national health systems. It has also reinvigorated a debate about the right way to prioritize and use development assistance for health (DAH).
YouTube Recording: https://youtu.be/yVotbI-93ek
 
 
Chatham House [to 02 Apr 2022]
https://www.chathamhouse.org/
Accessed 02 Apr 2022
Pandemic: Needled by the rulebook
At last, there is a new proposal for a waiver on Covid-19 vaccine patents, but it is a far from useful compromise, says James Love
The World Today 1 April 2022
James Love, Director of Knowledge Ecology International

 
 
CSIS
https://www.csis.org/
Accessed 02 Apr 2022
[No new digest content identified]

 
 

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 02 Apr 2022
March 28, 2022 News Release
Many Uninsured People Could Lose Access to Free COVID-19 Testing, Treatment, and Vaccines as Federal Funding Runs Out
With an impasse in Congress over additional COVID-19 emergency funding, uninsured people could lose access to free testing and treatment services, a new KFF brief explains. For people without health insurance, the Health Resources and Services Administration (HRSA) COVID-19 Uninsured Program has reimbursed hospitals, doctors and other providers for the…
 
 
Rand [to 02 Apr 2022]
https://www.rand.org/pubs.html
Reports, Selected Journal Articles
Report
Understanding Competition: Great Power Rivalry in a Changing International Order — Concepts and Theories
U.S. national security policy for the foreseeable future will likely be oriented around competition with China and Russia. The author reviews U.S. government strategy, RAND research, and other sources to help explain international competitions.
Mar 30, 2022
Michael J. Mazarr